Radiopharmaceuticals Market
Radiopharmaceuticals uptake receiving traction amid Increasing Patient awareness, disease-targeted cancer therapy, and use of molecular imaging
Radiopharmaceuticals Market by Radioisotope Type, Application, Source, End-user, Region | Forecast 2022 to 2032
Radiopharmaceuticals Market Snapshot (2022 to 2032)
According to Future Market Insights (FMI), the radiopharmaceuticals market would be worth US$ 6.2 Billion in 2022. During the forecast period ranging from 2022 to 2032, radiopharmaceuticals uptake is anticipated to flourish at a value CAGR of 4.3% to reach US$ 9.5 Billion.
Because of the rising frequency of cancer cases and the expansion of the healthcare industry in the USA and Canada, North America will account for more than 47% of the worldwide market.
According to Future Market Insights, notable participants include Siemens AG, General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler. In the worldwide radiopharmaceuticals market, the top companies account for over 90% of revenue.
|
Data Points |
Key Statistics |
|
Radiopharmaceuticals Market Value 2022 |
US$ 6.2 Billion |
|
Radiopharmaceuticals Market Projected Value (2032) |
US$ 9.5 Billion |
|
Radiopharmaceuticals Market CAGR (2022 to 2032) |
4.3% |
Let us know your requirement to get
100% FREE customization
Radiopharmaceuticals Demand Analysis (2016 to 2021) Vs Market Outlook (2022 to 2032)
The global demand for radiopharmaceuticals is projected to increase at a CAGR of 4.3% during the forecast period between 2022 and 2032, reaching a total of US$ 9.5 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 3.8%.
Improving radio-therapeutic penetration is predicted to be the primary driver of the radiopharmaceutical market. Radiopharmaceuticals are rapidly being utilized to diagnose and treat a variety of ailments, including cancer, cardiovascular disease, and neurological problems. Radiopharmaceuticals are widely utilized in the treatment of certain disorders due to the properties of radioactive decay and the possibility of focused therapeutic irradiation. However, the unusual outbreak of COVID-19 hampered market expansion.
Radioisotope production has ceased worldwide, as have research efforts. The worldwide market value fell as a result of disruptions in the demand and supply chains. The rapid use of sophisticated nuclear imaging technologies such as SPECT and Positron Emission Tomography (PET) will considerably contribute to market development. Radiopharmaceuticals' market expansion is being aided by increased research and development from key players.
GE Healthcare, for example, provided cloud and IT-based solutions and apps to link medical imaging with analytics and insights. The growing clinical uses of radiopharmaceuticals in cancer, cardiology, endocrinology, and neurology are boosting the market growth.
Which Drivers underpin Radiopharmaceuticals Industry Expansion?
Developing Centralized Pharmacies to Support Growth
There is a dearth of codified good manufacturing practice (GMP) requirements in the radiopharmaceutical sector, as well as rigid laws controlling the use of radiopharmaceuticals. To solve quality assurance difficulties, nuclear medicine practitioners are advocating for the establishment of centralized radio pharmacies.
This is because administrators and lawmakers are becoming increasingly interested in radiopharmaceutical, Positron Emission Tomography (PET), and clinical trial laws. A centralized radiopharmacy concept provides various benefits to patients and governing authorities, including the capacity to dispense patient-specific prescriptions and supply requested items from all sources and services accessible. These activities are projected to enhance market expansion throughout the forecast period.
Increasing Disease Prevalence is Accelerating the Market Growth
One of the prominent drivers fueling market expansion is the rising prevalence of acute and chronic illnesses such as cancer throughout the world as a result of numerous causes. Radiopharmaceuticals allow for the detection of tumor cells in organs or across the body. Cancer is the world's second-largest cause of death.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors are limiting the Growth of Radiopharmaceuticals Market?
Expensive Costs Connected with Research and Development Capabilities to Impede the Market Growth
Expensive costs connected with Research and Development capabilities, inadequate infrastructure facilities, the short half-life of radiopharmaceuticals, high equipment prices, and a lack of awareness in backward economies are predicted to stymie market expansion.
In addition, a lack of favorable reimbursement scenarios and technology penetration in developing economies, hospital budget cuts, particularly during pandemics, and a lack of suitable infrastructure in low- and middle-income countries are expected to pose challenges to the market during the forecast period.
Country-wise Insights
Will North America Continue Dominance in the Global Radiopharmaceuticals Market?
Increased Frequency of Cancer and Cardiovascular Illnesses to Fuel the Market Growth
Because of its large number of healthcare facilities, expanding overweight population, large patient population suffering from chronic diseases such as cancer, cardiovascular disorders, and strokes, and rising number of research activities, North America dominates the radiopharmaceuticals market.
The increased frequency of cancer and cardiovascular illnesses in the United States is driving the growth of the radiopharmaceuticals market. Nuclear medicine sales have increased due to an aging population and bad lifestyle choices, which have resulted in an increase in cancer and obesity cases. The adoption of innovative radioisotope manufacturing methods to treat these disorders is expected to boost the country's radiopharmaceutical growth. The American Heart Association estimates that 17.3 million people die each year as a result of cardiovascular disease.
Radiopharmaceuticals provide radiologists an advantage in the treatment of various disorders. Targeted medicines and sophisticated technologies incorporated in cyclotrons for the treatment of cardiovascular disease and cancer will boost radiopharmaceutical demand in the USA. Based on the above, the USA will dominate the North American radiopharmaceuticals market throughout the projection period, accounting for more than 45% of the market share.
Where does the growth of the Radiopharmaceuticals Market in Asia Pacific Excluding Japan stand?
Expansion of the Healthcare Industry to fuel Market Growth
Product launches, acquisitions, distribution agreements, collaborations, and regional expansion by local firms, notably in India, are projected to boost the radiopharmaceuticals market in the Asia Pacific Excluding Japan.
The expansion of the healthcare industry and the adoption of improved technologies are the primary drivers of the radiopharmaceutical market in India. Along with this, the country's high cancer prevalence has boosted the use of targeted medicines and enhanced radioisotope manufacturing.
The growing inclination for non-invasive medicines in India, as well as the great effectiveness provided by radiopharmaceuticals, is the primary reasons why radiopharmaceuticals are booming. Government and commercial healthcare organizations are expanding financing and Research and Development efforts to produce efficient tailored medicines with fewer adverse effects.
The incorporation of cutting-edge technology in the development of sophisticated radiotracers for the treatment of cancer and cardiovascular disease is assisting in the expansion. Several research projects launched by the National Cancer Institute have increased the manufacturing and use of radioisotopes for cancer therapy in India.
Why is the need for radiopharmaceuticals increasing in the United Kingdom?
Rising Incidences of Cancer in the Region to Accelerate Market
The United Kingdom is likely to be a major country in Europe, accounting for the largest proportion of the European radiopharmaceuticals market. Cancer is becoming more common in the United Kingdom resulting in increased production of radioisotopes for enhanced molecular imaging and cancer therapy treatments Radiopharmaceutical advantages, such as high effectiveness and non-invasive external monitoring, have encouraged radioisotope manufacturing.
According to a Cancer Research United Kingdom estimate, roughly 367,167 cancer cases are diagnosed in the United Kingdom. Every year, around 166,000 cancer deaths are documented. Rising scenarios like this are expected to promote the expansion of the country's radiopharmaceutical industry. The expansion of healthcare infrastructure and more research on non-invasive targeted medicines to minimize the load would greatly increase radiopharmaceutical demand in the United Kingdom. The growing interest of healthcare professionals, administrators, and lawmakers in radiopharmaceutical, positron emission tomography, and clinical trial standards will undoubtedly boost market expansion.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
Which is the most Popular Application of Radiopharmaceuticals?
The Oncology Segment to Drive the Radiopharmaceuticals Market
The increasing prevalence of cancer and cardiovascular disorders such as coronary heart disease and heart failure throughout the world is providing a boost to market expansion. Increasing incidences of lifestyle disorders, obesity, and tumors caused by poor behaviors among the elderly are the primary forces driving up demand for radiopharmaceuticals. According to Future Market Insights, Inc, increased instances of breast cancer, lung cancer, and prostate cancer will drive sector growth.
The increasing use of nuclear medicine in cancer and cardiology is the primary driver of market expansion. According to the American Cancer Society, 1.9 million new cancer cases will be recorded in 2021, and about 608,570 people will die from cancer in the USA. With the number of cancer cases increasing, healthcare experts are creating innovative new approaches to produce nuclear medicine for therapy. The rapid adoption of sophisticated radiopharmaceutical methods for cancer treatment will drive growth.
Radiopharmaceuticals play an important role in cancer diagnosis and treatment by improving understanding of disease stages. According to Future Market Insights, the rising use of nuclear medicine in cancer will account for more than 50% of the worldwide market value by 2032.
The Start-up Ecosystem: How key Players are opening Frontiers for Future Growth?
Start-ups and their innovations are driving some of the most recent advances in the radiopharmaceuticals sector. Radiopharmaceuticals give the consumer a precise diagnosis and highlight some of the companies. Let's have a look at some of the primary areas of innovation in this industry:
- Theranostics, a British firm, creates radiopharmaceuticals based on fluorine-18. The primary medicine of the start-up, THG-008, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It assists in the imaging of head and neck cancer as well as brain cancer. THG-009, an iodine rPARPi, is also being developed by the company.
- Navigo Proteins is a German business that creates innovative radio conjugates. Affilin is a firm that creates artificial proteins that preferentially bind antigens and radio conjugates. This is accomplished by combining target-binding Affilin molecules with isotope-loaded chelators. The isotope-to-carrier ratios in the molecules are uniform. Researchers can fine-tune radio conjugates for theranostics by optimizing the loaded radionuclide and the conjugate's specific half-life. In addition, the company is working on precision capture and precision targeting technologies, such as antibody purification and cellular treatment.
- Naogen Pharma, a French firm, is developing rubidium-82 generators for CAD diagnosis. The company produces Rubidium-82 radionuclides using a strontium-82/rubidium-82 infuser and a strontium-82/rubidium-82 generator. This is directly connected to the veins of patients. The equipment, together with a positron emission tomography (PET) system, can be installed on the patient's bed. In addition, the firm offers PET scanning, cardiac ischemia detection, and other services.
Who are the Leading Players in the Radiopharmaceuticals Market?
According to Future Market Insights, market consolidation has resulted from intense rivalry among top competitors. The top five market participants are Siemens AG, G E Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler.
These top five players account for over 90% of the worldwide market share. The leading players' winning methods include providing innovative technology and nuclear medications for therapy.
Leading firms like GE Healthcare and Siemens Healthcare are working on providing innovative product-based innovations, pharmaceutical services, and IT-based solutions in order to preserve their industry leadership.
Recent Developments:
- In March 2021, Aktis Oncology, a biotechnology firm developing a unique class of targeted radiopharmaceuticals to treat a wide spectrum of solid tumor cancer patients, reported the completion of a solid tumor series.
- In November 2020, Fusion Pharmaceuticals, a top Canadian radiopharmaceuticals business, announced cooperation with Anglo-Swedish Pharma giant AstraZeneca to commercialize and develop next-generation alpha-emitting radiopharmaceuticals and combination treatments for cancer therapy.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 4.3% from 2022 to 2032 |
|
Market Value in 2022 |
US$ 6.2 Billion |
|
Market Value in 2032 |
US$ 9.5 Billion |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016 to 2021 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization & Pricing |
Available upon Request |
Key Segments Covered in the Radiopharmaceuticals Industry Analysis
Radiopharmaceuticals Market by Radioisotope Type:
- Technetium-99
- Fluorine-18
- Iodine-131
- Leutetium-177
- Yttrium-90
- Gallium-68
- Gallium-67
- Rubidium-82
- Iodine-123
- Iodine-125
- Indium-111
- Others
Radiopharmaceuticals Market by Application:
- Oncology
- Cardiology
- Gastroenterology
- Neuroendocrinology
- Neurology
- Nephrology
- Others
Radiopharmaceuticals Market by Source:
- Cyclotrons
- Nuclear Reactors
Radiopharmaceuticals Market by End User:
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
- Cancer Research Institute
Radiopharmaceuticals Market by Region:
- North America Radiopharmaceuticals Market
- Latin America Radiopharmaceuticals Market
- Western Europe Radiopharmaceuticals Market
- Eastern Europe Radiopharmaceuticals Market
- APEJ Radiopharmaceuticals Market
- Japan Radiopharmaceuticals Market
- Middle East & Africa Radiopharmaceuticals Market
Frequently Asked Questions
At what value did the radiopharmaceuticals market close in 2022?
By 2022 end, sales of radiopharmaceuticals closed at a value of US$ 6.2 Billion.
What was the last 5 years value CAGR for radiopharmaceuticals market value?
From 2016 to 2021, radiopharmaceuticals demand expanded at a CAGR of 3.8%
What is the projected forecast CAGR for the radiopharmaceuticals industry from 2022 to 2032?
From 2022 to 2032, radiopharmaceuticals sales are expected to flourish at a CAGR of 4.3%
According to FMI, what is the anticipated market value for radiopharmaceuticals in 2032?
By 2032, the market value of radiopharmaceuticals is expected to reach US$ 9.5 Billion
Table of Content
1. Executive Summary | Radiopharmaceuticals Market 1.1. Global Market Outlook 1.2. Global Market Share Analysis 1.3. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Macro-Economic Factors 3.1.1. Increasing healthcare expenditure as a percentage of GDP 3.1.2. Rise in the Aging population 3.2. Forecast Factors - Relevance & Impact 3.2.1. Increasing Installed base for PET and SPECT Scanners 3.2.2. Increasing Incidence of Cancer 3.2.3. Increasing Diagnosis Rate 3.3. Market Dynamics 3.3.1. Opportunity Analysis 3.3.2. Drivers 3.3.3. Restraints 3.3.4. Trends 4. Market Context 4.1. Reimbursement Scenario 4.2. Key Regulations 4.3. Value Chain Analysis 5. Global Market Demand (Size in US$ Million) Analysis 2016 to 2021 and Forecast, 2022 to 2032 5.1. Historical Market Value (US$ Million) Analysis, 2016 to 2021 5.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 5.3. Market Value Growth Comparison 6. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Radioisotope 6.1. Introduction / Key Findings 6.2. Historical Market Size (US$ Million) Analysis By Radioisotope, 2016 to 2021 6.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Radioisotope, 2022 to 2032 6.3.1. Technetium-99 6.3.2. Fluorine-18 6.3.3. Iodine-131 6.3.4. Leutetium-177 6.3.5. Yttrium-90 6.3.6. Gallium-68 6.3.7. Gallium-67 6.3.8. Rubidium-82 6.3.9. Iodine-123 6.3.10. Iodine-125 6.3.11. Indium-111 6.3.12. Others 6.4. Market Attractiveness Analysis By Radioisotope 7. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Application 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis By Application, 2016 to 2021 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2022 to 2032 7.3.1. Oncology 7.3.2. Cardiology 7.3.3. Gastroenterology 7.3.4. Neuroendocrinology 7.3.5. Neurology 7.3.6. Nephrology 7.3.7. Others 7.4. Market Attractiveness Analysis By Application 8. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Source 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Source, 2016 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Source, 2022 to 2032 8.3.1. Cyclotrons 8.3.2. Nuclear Reactors 8.4. Market Attractiveness Analysis By Source 9. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by End User 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By End User, 2016 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2022 to 2032 9.3.1. Hospitals 9.3.2. Diagnostic Imaging Centers 9.3.3. Ambulatory Surgical Centers 9.3.4. Cancer Research Institute 9.4. Market Attractiveness Analysis By End User 10. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, by Region 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Region, 2016 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032 10.3.1. North America 10.3.2. Latin America 10.3.3. Western Europe 10.3.4. Eastern Europe 10.3.5. Asia Pacific Excluding Japan 10.3.6. Japan 10.3.7. Middle East and Africa(MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2016 to 2021 and Forecast 2022 to 2032 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2016 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 11.3.1. By Country 11.3.1.1. USA 11.3.1.2. Canada 11.3.2. By Radioisotope 11.3.3. By Application 11.3.4. By Source 11.3.5. By End User 11.4. Market Attractiveness Analysis 11.4.1. By Country 11.4.2. By Radioisotope 11.4.3. By Application 11.4.4. By Source 11.4.5. By End User 12. Latin America Market Analysis 2016 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2016 to 2021 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Rest of Latin America 12.3.2. By Radioisotope 12.3.3. By Application 12.3.4. By Source 12.3.5. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Radioisotope 12.4.3. By Application 12.4.4. By Source 12.4.5. By End User 13. Western Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2016 to 2021 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. United Kingdom 13.3.1.3. France 13.3.1.4. Spain 13.3.1.5. Italy 13.3.1.6. Nordic Countries 13.3.1.7. Benelux 13.3.1.8. Rest of Western Europe 13.3.2. By Radioisotope 13.3.3. By Application 13.3.4. By Source 13.3.5. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Radioisotope 13.4.3. By Application 13.4.4. By Source 13.4.5. By End User 14. Eastern Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2016 to 2021 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Russia 14.3.1.2. Poland 14.3.1.3. Rest of EE 14.3.2. By Radioisotope 14.3.3. By Application 14.3.4. By Source 14.3.5. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Radioisotope 14.4.3. By Application 14.4.4. By Source 14.4.5. By End User 15. APEJ Market Analysis 2016 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2016 to 2021 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. China 15.3.1.2. India 15.3.1.3. Australia & New Zealand 15.3.1.4. ASEAN 15.3.1.5. Rest of Asia Pacific Excluding Japan 15.3.2. By Radioisotope 15.3.3. By Application 15.3.4. By Source 15.3.5. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Radioisotope 15.4.3. By Application 15.4.4. By Source 15.4.5. By End User 16. Japan Market Analysis 2016 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2016 to 2021 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 16.3.1. By Radioisotope 16.3.2. By Application 16.3.3. By Source 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Radioisotope 16.4.2. By Application 16.4.3. By Source 16.4.4. By End User 17. Middle East and Africa Market Analysis 2016 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2016 to 2021 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. GCC Countries 17.3.1.2. South Africa 17.3.1.3. Rest of Middle East and Africa(MEA) 17.3.2. By Radioisotope 17.3.3. By Application 17.3.4. By Source 17.3.5. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Radioisotope 17.4.3. By Application 17.4.4. By Source 17.4.5. By End User 18. Competition Analysis 18.1. Competition Dashboard 18.2. Competition Benchmarking 18.3. Competition Deep Dive 18.3.1. Siemens AG (Siemens Healthineers) 18.3.1.1. Overview 18.3.1.2. Service Portfolio 18.3.1.3. Profitability by Market Segments (Service/Channel/Region) 18.3.1.4. Sales Footprint 18.3.1.5. Strategy Overview 18.3.1.5.1. Marketing Strategy 18.3.1.5.2. Service Strategy 18.3.1.5.3. Channel Strategy 18.3.2. Positron Corporation 18.3.2.1. Overview 18.3.2.2. Service Portfolio 18.3.2.3. Profitability by Market Segments (Service/Channel/Region) 18.3.2.4. Sales Footprint 18.3.2.5. Strategy Overview 18.3.2.5.1. Marketing Strategy 18.3.2.5.2. Service Strategy 18.3.2.5.3. Channel Strategy 18.3.3. Novartis (Advanced Accelerator Applications) 18.3.3.1. Overview 18.3.3.2. Service Portfolio 18.3.3.3. Profitability by Market Segments (Service/Channel/Region) 18.3.3.4. Sales Footprint 18.3.3.5. Strategy Overview 18.3.3.5.1. Marketing Strategy 18.3.3.5.2. Service Strategy 18.3.3.5.3. Channel Strategy 18.3.4. Curium 18.3.4.1. Overview 18.3.4.2. Service Portfolio 18.3.4.3. Profitability by Market Segments (Service/Channel/Region) 18.3.4.4. Sales Footprint 18.3.4.5. Strategy Overview 18.3.4.5.1. Marketing Strategy 18.3.4.5.2. Service Strategy 18.3.4.5.3. Channel Strategy 18.3.5. GE Healthcare 18.3.5.1. Overview 18.3.5.2. Service Portfolio 18.3.5.3. Profitability by Market Segments (Service/Channel/Region) 18.3.5.4. Sales Footprint 18.3.5.5. Strategy Overview 18.3.5.5.1. Marketing Strategy 18.3.5.5.2. Service Strategy 18.3.5.5.3. Channel Strategy 18.3.6. Lantheus Holdings, Inc. 18.3.6.1. Overview 18.3.6.2. Service Portfolio 18.3.6.3. Profitability by Market Segments (Service/Channel/Region) 18.3.6.4. Sales Footprint 18.3.6.5. Strategy Overview 18.3.6.5.1. Marketing Strategy 18.3.6.5.2. Service Strategy 18.3.6.5.3. Channel Strategy 18.3.7. Sotera Health LLC (Nordion, Inc.) 18.3.7.1. Overview 18.3.7.2. Service Portfolio 18.3.7.3. Profitability by Market Segments (Service/Channel/Region) 18.3.7.4. Sales Footprint 18.3.7.5. Strategy Overview 18.3.7.5.1. Marketing Strategy 18.3.7.5.2. Service Strategy 18.3.7.5.3. Channel Strategy 18.3.8. Bayer AG 18.3.8.1. Overview 18.3.8.2. Service Portfolio 18.3.8.3. Profitability by Market Segments (Service/Channel/Region) 18.3.8.4. Sales Footprint 18.3.8.5. Strategy Overview 18.3.8.5.1. Marketing Strategy 18.3.8.5.2. Service Strategy 18.3.8.5.3. Channel Strategy 18.3.9. Eckert & Ziegler 18.3.9.1. Overview 18.3.9.2. Service Portfolio 18.3.9.3. Profitability by Market Segments (Service/Channel/Region) 18.3.9.4. Sales Footprint 18.3.9.5. Strategy Overview 18.3.9.5.1. Marketing Strategy 18.3.9.5.2. Service Strategy 18.3.9.5.3. Channel Strategy 19. Assumptions and Acronyms Used 20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Million) Growth Comparison Table 02: Global Market Value (US$ Million) Analysis and Opportunity Assessment 2022 to 2032, By Radioisotope Table 03: Global Market Value (US$ Million) Analysis and Opportunity Assessment 2022 to 2032, By Application Table 04: Global Market Value (US$ Million) Analysis and Opportunity Assessment 2022 to 2032, By Source Table 05: Global Market Value (US$ Million) Analysis and Opportunity Assessment 2022 to 2032, By End User Table 06: Global Market Value (US$ Million) Analysis and Opportunity Assessment 2022 to 2032, By Region Table 07: North America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country Table 08: North America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Radioisotope Table 09: North America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application Table 10: North America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Source Table 11: North America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User Table 12: Latin America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country Table 13: Latin America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Radioisotope Table 14: Latin America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application Table 15: Latin America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Source Table 16: Latin America Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User Table 17: Western Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country Table 18: Western Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Radioisotope Table 19: Western Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application Table 20: Western Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Source Table 21: Western Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User Table 22: Eastern Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country Table 23: Eastern Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Radioisotope Table 24: Eastern Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application Table 25: Eastern Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Source Table 26: Eastern Europe Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User Table 27: APEJ Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country Table 28: APEJ Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Radioisotope Table 29: APEJ Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application Table 30: APEJ Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Source Table 31: APEJ Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User Table 32: Japan Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Radioisotope Table 33: Japan Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application Table 34: Japan Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Source Table 35: Japan Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User Table 36: Middle East and Africa(MEA) Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country Table 37: Middle East and Africa(MEA) Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Radioisotope Table 38: Middle East and Africa(MEA) Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Application Table 39: Middle East and Africa(MEA) Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By Source Table 40: Middle East and Africa(MEA) Market Value (US$ Million) Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Revenue Share by Radioisotope, 2021E & 2031F Figure 02: Global Market Revenue Share by Application, 2021E & 2031F Figure 03: Global Market Revenue Share by Source, 2021E & 2031F Figure 04: Global Market Revenue Share by End User, 2021E & 2031F Figure 05: Global Market Revenue Share by Region, 2021E & 2031F Figure 06: Market Value Analysis and Forecast 2021 to 2031 (US$ Million) Figure 07: Market Value (US$ Million), 2016 to 2020 Figure 08: Market Absolute $ Opportunity (US$ Million), 2022 to 2032 Figure 09: Comparison of February 2017 and October 2021, Y-o-Y Forecast Figure 10: Global Market Share Analysis (%), By Radioisotope, 2021 & 2031 Figure 11: Global Market Y-o-Y Analysis (%), By Radioisotope, 2022 to 2032 Figure 12: Global Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 13: Global Market Share Analysis (%), By Application, 2021 & 2031 Figure 14: Global Market Y-o-Y Analysis (%), By Application, 2022 to 2032 Figure 15: Global Market Attractiveness Analysis by Application, 2022 to 2032 Figure 16: Global Market Share Analysis (%), By Source, 2021 & 2031 Figure 17: Global Market Y-o-Y Analysis (%), By Source, 2022 to 2032 Figure 18: Global Market Attractiveness Analysis by Source, 2022 to 2032 Figure 19: Global Market Share Analysis (%), By End User, 2021 & 2031 Figure 20: Global Market Y-o-Y Analysis (%), By End User, 2022 to 2032 Figure 21: Global Market Attractiveness Analysis by End User, 2022 to 2032 Figure 22: Global Market Share Analysis (%), By Region, 2021 & 2031 Figure 23: Global Market Y-o-Y Analysis (%), By Region, 2022 to 2032 Figure 24: Global Market Attractiveness Analysis by Region, 2022 to 2032 Figure 25: North America Market Value Share, By Radioisotope (2022 E) Figure 26: North America Market Value Share, By Application (2022 E) Figure 27: North America Market Value Share, By Source (2022 E) Figure 28: North America Market Value Share, By End User (2022 E) Figure 29: North America Market Value Share, By Country (2022 E) Figure 30: North America Market Value Analysis (US$ Million), 2016-2021 Figure 31: North America Market Value Forecast (US$ Million), 2022 to 2032 Figure 32: North America Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 33: North America Market Attractiveness Analysis by Application, 2022 to 2032 Figure 34: North America Market Attractiveness Analysis by Source, 2022 to 2032 Figure 35: North America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 36: North America Market Attractiveness Analysis by Region, 2022 to 2032 Figure 37: Latin America Market Value Share, By Radioisotope (2022 E) Figure 38: Latin America Market Value Share, By Application (2022 E) Figure 39: Latin America Market Value Share, By Source (2022 E) Figure 40: Latin America Market Value Share, By End User (2022 E) Figure 41: Latin America Market Value Share, By Country (2022 E) Figure 42: Latin America Market Value Analysis (US$ Million),2016-2021 Figure 43: Latin America Market Value Forecast (US$ Million), 2022 to 2032 Figure 44: Latin America Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 45: Latin America Market Attractiveness Analysis by Application, 2022 to 2032 Figure 46: Latin America Market Attractiveness Analysis by Source, 2022 to 2032 Figure 47: Latin America Market Attractiveness Analysis by End User, 2022 to 2032 Figure 48: Latin America Market Attractiveness Analysis by Region, 2022 to 2032 Figure 49: Western Europe Market Value Share, By Radioisotope (2022 E) Figure 50: Western Europe Market Value Share, By Application (2022 E) Figure 51: Western Europe Market Value Share, By Source (2022 E) Figure 52: Western Europe Market Value Share, By End User (2022 E) Figure 53: Western Europe Market Value Share, By Country (2022 E) Figure 54: Western Europe Market Value Analysis (US$ Million),2016-2021 Figure 55: Western Europe Market Value Forecast (US$ Million), 2022 to 2032 Figure 56: Western Europe Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 57: Western Europe Market Attractiveness Analysis by Application, 2022 to 2032 Figure 58: Western Europe Market Attractiveness Analysis by Source, 2022 to 2032 Figure 59: Western Europe Market Attractiveness Analysis by End User, 2022 to 2032 Figure 60: Western Europe Market Attractiveness Analysis by Region, 2022 to 2032 Figure 61: Eastern Europe Market Value Share, By Radioisotope (2022 E) Figure 62: Eastern Europe Market Value Share, By Application (2022 E) Figure 63: Eastern Europe Market Value Share, By Source (2022 E) Figure 64: Eastern Europe Market Value Share, By End User (2022 E) Figure 65: Eastern Europe Market Value Share, By Country (2022 E) Figure 66: Eastern Europe Market Value Analysis (US$ Million),2016-2021 Figure 67: Eastern Europe Market Value Forecast (US$ Million), 2022 to 2032 Figure 68: Eastern Europe Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 69: Eastern Europe Market Attractiveness Analysis by Application, 2022 to 2032 Figure 70: Eastern Europe Market Attractiveness Analysis by Source, 2022 to 2032 Figure 71: Eastern Europe Market Attractiveness Analysis by End User, 2022 to 2032 Figure 72: Eastern Europe Market Attractiveness Analysis by Region, 2022 to 2032 Figure 73: APEJ Market Value Share, By Radioisotope (2022 E) Figure 74: APEJ Market Value Share, By Application (2022 E) Figure 75: APEJ Market Value Share, By Source (2022 E) Figure 76: APEJ Market Value Share, By End User (2022 E) Figure 77: APEJ Market Value Share, By Country (2022 E) Figure 78: APEJ Market Value Analysis (US$ Million),2016-2021 Figure 79: APEJ Market Value Forecast (US$ Million), 2022 to 2032 Figure 80: APEJ Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 81: APEJ Market Attractiveness Analysis by Application, 2022 to 2032 Figure 82: APEJ Market Attractiveness Analysis by Source, 2022 to 2032 Figure 83: APEJ Market Attractiveness Analysis by End User, 2022 to 2032 Figure 84: APEJ Market Attractiveness Analysis by Region, 2022 to 2032 Figure 85: Japan Market Value Share, By Radioisotope (2022 E) Figure 86: Japan Market Value Share, By Application (2022 E) Figure 87: Japan Market Value Share, By Source (2022 E) Figure 88: Japan Market Value Share, By End User (2022 E) Figure 89: Japan Market Value Analysis (US$ Million),2016-2021 Figure 90: Japan Market Value Forecast (US$ Million), 2022 to 2032 Figure 91: Japan Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 92: Japan Market Attractiveness Analysis by Application, 2022 to 2032 Figure 93: Japan Market Attractiveness Analysis by Source, 2022 to 2032 Figure 94: Japan Market Attractiveness Analysis by End User, 2022 to 2032 Figure 95: Middle East and Africa(MEA) Market Value Share, By Radioisotope (2022 E) Figure 96: Middle East and Africa(MEA) Market Value Share, By Application (2022 E) Figure 97: Middle East and Africa(MEA) Market Value Share, By Source (2022 E) Figure 98: Middle East and Africa(MEA) Market Value Share, By End User (2022 E) Figure 99: Middle East and Africa(MEA) Market Value Share, By Country (2022 E) Figure 100: Middle East and Africa(MEA) Market Value Analysis (US$ Million),2016-2021 Figure 101: Middle East and Africa(MEA) Market Value Forecast (US$ Million), 2022 to 2032 Figure 102: Middle East and Africa(MEA) Market Attractiveness Analysis by Radioisotope, 2022 to 2032 Figure 103: Middle East and Africa(MEA) Market Attractiveness Analysis by Application, 2022 to 2032 Figure 104: Middle East and Africa(MEA) Market Attractiveness Analysis by Source, 2022 to 2032 Figure 105: Middle East and Africa(MEA) Market Attractiveness Analysis by End User, 2022 to 2032 Figure 106: Middle East and Africa(MEA) Market Attractiveness Analysis by Region, 2022 to 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
